Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.
Dr. Sandy Srinivas
United States: Institutional Review Board
|Stanford University School of Medicine||Stanford, California 94305-5317|